Phytocompounds and Nanoformulations for Anticancer Therapy: A Review
Molecules · 09.08.2024 · 29 (16) · 3784
DOI: 10.3390/molecules29163784 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 09.08.2024. Verfasst von Giuseppina Bozzuto und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Drug Research and Evaluation, Italian National Institute of Health, 00161 Rome, Italy. Hauptthemen laut MEDLINE: Phytochemicals, Neoplasms, Nanoparticles. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 335 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer is a complex disease that affects millions of people and remains a major public health problem worldwide. Conventional cancer treatments, including surgery, chemotherapy, immunotherapy, and radiotherapy, have limited achievements and multiple drawbacks, among which are healthy tissue damage and multidrug-resistant phenotype onset. Increasing evidence shows that many plants’ natural products, as well as their bioactive compounds, have promising anticancer activity and exhibit minimal toxicity compared to conventional anticancer drugs. However, their widespread use in cancer therapy is severely restricted by limitations in terms of their water solubility, absorption, lack of stability, bioavailability, and selective targeting. The use of nanoformulations for plants’ natural product transportation and delivery could be helpful in overcoming these limitations, thus enhancing their therapeutic efficacy and providing the basis for improved anticancer treatment strategies. The present review is aimed at providing an update on some phytocompounds (curcumin, resveratrol, quercetin, and cannabinoids, among others) and their main nanoformulations showing antitumor activities, both in vitro and in vivo, against such different human cancer types as breast and colorectal cancer, lymphomas, malignant melanoma, glioblastoma multiforme, and osteosarcoma. The intracellular pathways underlying phytocompound anticancer activity and the main advantages of nanoformulation employment are also examined. Finally, this review critically analyzes the research gaps and limitations causing the limited success of phytocompounds’ and nanoformulations’ clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Center for Drug Research and Evaluation, Italian National Institute of Health, 00161 Rome, Italy.
- Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.
ORCID-Profile: Giuseppina Bozzuto, Annarica Calcabrini, Marisa Colone, Maria Condello, Maria Luisa Dupuis, Evelin Pellegrini, Annarita Stringaro
Zitieren
APA
Bozzuto, G., Calcabrini, A., Colone, M., Condello, M., Dupuis, M. L., Pellegrini, E., & Stringaro, A. (2024). Phytocompounds and Nanoformulations for Anticancer Therapy: A Review. Molecules, 29(16), 3784. https://doi.org/10.3390/molecules29163784
Vancouver
Bozzuto G, Calcabrini A, Colone M, Condello M, Dupuis ML, Pellegrini E, et al. Phytocompounds and Nanoformulations for Anticancer Therapy: A Review. Molecules. 2024;29(16):3784. doi:10.3390/molecules29163784
BibTeX
@article{Bozzuto2024,
author = {Bozzuto, Giuseppina and Calcabrini, Annarica and Colone, Marisa and Condello, Maria and Dupuis, Maria Luisa and Pellegrini, Evelin and Stringaro, Annarita},
title = {Phytocompounds and Nanoformulations for Anticancer Therapy: A Review},
journal = {Molecules},
year = {2024},
volume = {29},
number = {16},
pages = {3784},
doi = {10.3390/molecules29163784}
}
EUVIMED